The FASN inhibitor attenuates the metastasis of different tumors, such as melanomas, breast cancer, oral cancer, and colorectal cancer (Seguin et al., 2012; Zaytseva et al., 2012, 2015; Agostini et al., 2014; Singh et al., 2015). Here, FASN is linked to melanoma.